This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.
This week we discuss the BiRT trial. It has long been a dogma to treat asymptomatic bacteriuria in kidney transplant recipients. Let’s upend this accepted truth by discussing the BiRT trial.
This week we discuss the AKi Alert trial from BMJ. Surely alerting us to AKI earlier will be helpful, right? Maybe - or maybe not. Join us to discuss this very important trial with some counter intuitive results.
Was MENTOR the final word for Rituximab in Membranous Nephropathy? Not so. We discuss STARMEN this week which compared sequential tacrolimus- rituximab with the Ponticelli protocol.
This week, we look at using the, marginally effective, Covid treatment, remdesivir in patients with decreased GFR against the advice of the manufacturer and the FDA.
Glomeruli seem fun and interesting, but the final common pathway for all kidney diseases is fibrosis. Irreversible and relentless once it sets in. Here we discuss some meticulous and groundbreaking work on how this develops, using really cool techniques.
This is the first, yes, the first time we are discussing a trial in SLE patients. Belimumab, which inhibits BAFF also called BLyS (hence the BLISS trials) in lupus nephritis. Added to a background of standard therapy - what does it give us? Let’s dive in.
This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.
This week, we will discuss the fresh-off-the-press KDIGO guidelines on Diabetes. RAS Blockade and SGLT2i, needless to say - but is there more? There is. Read on as we break it down for you.
SGLT2 inhibitors lower MACE in Diabetes. Then they decrease kidney failure in DM. Then Heart Failure in DM and non-DM. And now decrease kidney failure in nonDM too! Let’s see how strong the data really is
Its book club time! We will be discussing Rana Awdish’s bestseller, the searing first person narrative of a doctor going through a critical illness. And almost dying.
This week, we will discuss the social media issue in Seminars of Nephrology. The discussion will be anchored by two articles - but the whole issue is up for discussion.
This week, we will discuss the fresh-off-the-press trials from this week’s issue of the NEJM: PERL and CKD-FiX. These two trials examined if the uric acid and CKD link is causal: by measuring CKD progression after giving patients allopurinol. Be ready for another medical reversal.
This week, we will discuss the correct way to diagnose primary aldosteronism. Is a spot ARR sufficient? Prepare to turn whatever you thought you knew about PA around.
SGLT2i are the wonder drug for our age. But do we know how they work? How does their natriuretic effect actually work? Let’s dig deeper into this week’s mechanistic study that explores this question